TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer

Wherry, 2011, T cell exhaustion, Nat. Immunol., 12, 492, 10.1038/ni.2035 Thommen, 2018, T cell dysfunction in cancer, Canc. Cell, 33, 547, 10.1016/j.ccell.2018.03.012 McLane, 2019, CD8 T cell exhaustion during chronic viral infection and cancer, Annu. Rev. Immunol., 37, 457, 10.1146/annurev-immunol-041015-055318 Wherry, 2015, Molecular and cellular insights into T cell exhaustion, Nat. Rev. Immunol., 15, 486, 10.1038/nri3862 Hashimoto, 2018, CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions, Annu. Rev. Med., 69, 301, 10.1146/annurev-med-012017-043208 Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060 Doering, 2012, Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory, Immunity, 37, 1130, 10.1016/j.immuni.2012.08.021 Kim, 2018, Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma, Gastroenterology, 155, 1936, 10.1053/j.gastro.2018.08.030 Utzschneider, 2016, T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections, Immunity, 45, 415, 10.1016/j.immuni.2016.07.021 Siddiqui, 2019, Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy, Immunity, 50, 195, 10.1016/j.immuni.2018.12.021 Kao, 2011, Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection, Nat. Immunol., 12, 663, 10.1038/ni.2046 Paley, 2012, Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection, Science, 338, 1220, 10.1126/science.1229620 O'Flaherty, 2003, TOX defines a conserved subfamily of HMG-box proteins, BMC Genom., 4, 13, 10.1186/1471-2164-4-13 Seo, 2019, TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion, Proc. Natl. Acad. Sci. U. S. A., 116, 12410, 10.1073/pnas.1905675116 Khan, 2019, TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion, Nature, 571, 211, 10.1038/s41586-019-1325-x Scott, 2019, TOX is a critical regulator of tumour-specific T cell differentiation, Nature, 571, 270, 10.1038/s41586-019-1324-y Alfei, 2019, TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection, Nature, 571, 265, 10.1038/s41586-019-1326-9 Yao, 2019, Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection, Nat. Immunol., 20, 890, 10.1038/s41590-019-0403-4 Wang, 2019, TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma, J. Hepatol., 71, 731, 10.1016/j.jhep.2019.05.015 Kim, 2019, VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers, Sci Immunol, 4, 10.1126/sciimmunol.aay0555 Siegel, 2020, Cancer statistics, 2020, Ca - Cancer J. Clin., 70, 7, 10.3322/caac.21590 Sanli, 2017, Bladder cancer, Nat Rev Dis Primers, 3, 17022, 10.1038/nrdp.2017.22 Yarchoan, 2019, PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers, JCI Insight, 4, 126908, 10.1172/jci.insight.126908 Necchi, 2020, Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder, Eur. Urol., 77, 548, 10.1016/j.eururo.2020.01.003 Siefker-Radtke, 2018, Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition, Nat. Rev. Urol., 15, 112, 10.1038/nrurol.2017.190 Schneider, 2019, The multifaceted immune regulation of bladder cancer, Nat. Rev. Urol., 16, 613, 10.1038/s41585-019-0226-y Bellmunt, 2017, KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N. Engl. J. Med., 376, 1015, 10.1056/NEJMoa1613683 Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol., 18, 1483, 10.1016/S1470-2045(17)30616-2 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol., 18, 312, 10.1016/S1470-2045(17)30065-7 Simoni, 2018, Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates, Nature, 557, 575, 10.1038/s41586-018-0130-2 Duhen, 2018, Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors, Nat. Commun., 9, 2724, 10.1038/s41467-018-05072-0 Aktas, 2009, Relationship between CD107a expression and cytotoxic activity, Cell. Immunol., 254, 149, 10.1016/j.cellimm.2008.08.007 Powles, 2018, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 391, 748, 10.1016/S0140-6736(17)33297-X Sekine, 2020, TOX is expressed by exhausted and polyfunctional human effector memory CD8 + T cells, Sci Immunol, 5, 10.1126/sciimmunol.aba7918 Utzschneider, 2020, Human effector T cells express TOX-not so "TOX"ic after all, Sci Immunol, 5, 10.1126/sciimmunol.abc8272 Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, Nat. Immunol., 10, 48, 10.1038/ni.1674 Johnston, 2014, The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function, Canc. Cell, 26, 923, 10.1016/j.ccell.2014.10.018 Chauvin, 2015, TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients, J. Clin. Invest., 125, 2046, 10.1172/JCI80445 He, 2017, CD155T/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer, Canc. Res., 77, 6375, 10.1158/0008-5472.CAN-17-0381 Hung, 2018, TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM, OncoImmunology, 7 Audenet, 2018, Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer, World J. Urol., 36, 1741, 10.1007/s00345-018-2359-7 Le Goux, 2017, mRNA Expression levels of genes involved in antitumor immunity: identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer, OncoImmunology, 6, 10.1080/2162402X.2017.1358330 Manieri, 2017, TIGIT: a key inhibitor of the cancer immunity cycle, Trends Immunol., 38, 20, 10.1016/j.it.2016.10.002 Walker, 2011, The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses, Nat. Rev. Immunol., 11, 852, 10.1038/nri3108 Kong, 2016, T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients, Clin. Canc. Res., 22, 3057, 10.1158/1078-0432.CCR-15-2626 Rodriguez-Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). DOI: 10.1200/JCO.2020.38.15_suppl.9503 J. Clin. Oncol. 38, no. 15_suppl (May 20, 2020) 9503-9503.